Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Cancer Res. 2015 Feb 20;75(7):1423–1432. doi: 10.1158/0008-5472.CAN-13-3451

Figure 3. ONC201/TIC10 prevents CSC-mediated xenograft tumor growth and self-renewal in vivo.

Figure 3

(A) ONC201/TIC10 prevents CSC-mediated xenograft tumor growth. Sorted DLD1 Aldefluor(+) cells were subcutaneously injected into the right and left flank of athymic nude mice. Upon tumor formation, mice were administered either vehicle or ONC201/TIC10 50 mg/kg (i.p.). (N = 7 per group) Doses (indicated by triangle) were administered post-tumor implantation on day 7, 14 and 22. Tumor growth was monitored until the endpoint. Data is presented as mean ± standard error of mean. * indicates p < 0.05. (B) Representative image for (A). (C) Body weight of mice in (A) was monitored along with tumor growth until the end point. (D) Immunohistochemistry analysis of harvested tumors from (A) for CSC markers and TRAIL. (E) Sorted Aldefluor(+) DLD1 cells were plated for colonosphere culture in the presence of DMSO or 50 μM 5-FU or 5 μM ONC201/TIC10 for 72 h. Viable cells were counted and the indicated number of cells were injected into the right and left flank of hairless SCID mice. Tumor initiation was monitored till Day 80 post tumor implantation.